The press release highlights the brain infection–Alzheimer’s disease link through brain microbiome research and the immune system’s role in amyloid and tau overproduction.

The release reiterates buntanetap’s ongoing Phase 3 program for neurodegenerative diseases and states that the patent strengthens the company’s long-term IP position and lifecycle management.

Maria Maccecchini, Ph.D., Annovis’ President and CEO, emphasizes protecting buntanetap’s potential across all patient-benefiting avenues and the relevance of microbial/viral infection in neurodegenerative initiation.

The CEO underscores the importance of safeguarding buntanetap’s potential across avenues where it may benefit patients, highlighting infection-related initiation as a key context.

Annovis Bio announced the issuance of U.S. Patent No. 12,582,632 B2 for buntanetap, covering prevention and treatment of neurological injuries caused by brain infections across viral, bacterial, fungal, protozoan and parasitic agents, with protection extending through 2044.

The patent describes buntanetap’s mechanism of action as reducing the translational overproduction of neurotoxic proteins like amyloid-beta and tau, which are linked to neurodegeneration and may be triggered by infections.

Company executives say the patent strengthens Annovis’ intellectual property estate and positions buntanetap within broader research on infection-related neurodegeneration.

The article includes standard company background, investor contact details, and a disclaimer that the content reflects the author’s opinion and is not investment advice.

Forward-looking statements acknowledge risks and uncertainties, with potential deviations from projected outcomes in typical biotech disclosures.

Investors are encouraged to register for email alerts and review SEC filings for risk factors and additional disclosures.

The patent announcement was issued via Globe Newswire, including standard forward-looking statements and investor contact information.

Market context notes modest pre-announcement trading interest, with the stock trading below its 200-day moving average, and suggests the patent news could influence partnerships and future infection-related neurodegeneration indications.